Plasma tumor DNA is associated with increased risk of venous thromboembolism in metastatic castration‐resistant cancer patients
暂无分享,去创建一个
E. Scarpi | H. Beltran | F. Demichelis | V. Conteduca | A. Romanel | D. Barone | U. de Giorgi | G. Schepisi | G. Gurioli | G. Attard | G. Paganelli | F. Matteucci | C. Lolli | D. Wetterskog | C. Gianni | N. Brighi | S. Bleve | F. Ferroni | A. Rossi | P. Cortesi
[1] A. Jemal,et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries , 2021, CA: a cancer journal for clinicians.
[2] Delila Gasi Tandefelt,et al. Plasma tumour DNA as an early indicator of treatment response in metastatic castration-resistant prostate cancer , 2020, British Journal of Cancer.
[3] Zhenlang Guo,et al. Association of androgen deprivation therapy with thromboembolic events in patients with prostate cancer: a systematic review and meta-analysis , 2018, Prostate Cancer and Prostatic Diseases.
[4] E. Scarpi,et al. Association among metabolic syndrome, inflammation, and survival in prostate cancer. , 2018, Urologic oncology.
[5] F. Bidard,et al. Circulating tumor cell count and thrombosis in metastatic breast cancer , 2017, Journal of thrombosis and haemostasis : JTH.
[6] D. Amadori,et al. Androgen receptor gene status in plasma DNA associates with worse outcome on enzalutamide or abiraterone for castration-resistant prostate cancer: a multi-institution correlative biomarker study , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.
[7] Matti Nykter,et al. Genomic Alterations in Cell-Free DNA and Enzalutamide Resistance in Castration-Resistant Prostate Cancer. , 2016, JAMA oncology.
[8] A. Cohen,et al. Cancer-associated venous thromboembolism: Burden, mechanisms, and management , 2016, Thrombosis and Haemostasis.
[9] Oliver Sartor,et al. Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] A. Aprikian,et al. Androgen Deprivation Therapy for Prostate Cancer and the Risk of Venous Thromboembolism. , 2016, European urology.
[11] Delila Gasi Tandefelt,et al. Plasma AR and abiraterone-resistant prostate cancer , 2015, Science Translational Medicine.
[12] T. Gould,et al. Extracellular DNA and histones: double‐edged swords in immunothrombosis , 2015, Journal of thrombosis and haemostasis : JTH.
[13] S. Braekkan,et al. Epidemiology of cancer-associated venous thrombosis. , 2013, Blood.
[14] V. Conteduca,et al. The cardiovascular risk of gonadotropin releasing hormone agonists in men with prostate cancer: an unresolved controversy. , 2013, Critical reviews in oncology/hematology.
[15] Jim C Hu,et al. Androgen-deprivation therapy for nonmetastatic prostate cancer is associated with an increased risk of peripheral arterial disease and venous thromboembolism. , 2012, European urology.
[16] J. Hansen,et al. Testosterone, Hemostasis, and Cardiovascular Diseases in Men , 2011, Seminars in Thrombosis & Hemostasis.
[17] Jonathan E. Dickerson,et al. Supplementary Webappendix , 2022 .
[18] V. Valero,et al. Circulating tumour cells are associated with increased risk of venous thromboembolism in metastatic breast cancer patients , 2009, British Journal of Cancer.
[19] Gary H Lyman,et al. Development and validation of a predictive model for chemotherapy-associated thrombosis. , 2008, Blood.
[20] Robert Gray,et al. A Proportional Hazards Model for the Subdistribution of a Competing Risk , 1999 .
[21] E L Korn,et al. Applications of crude incidence curves. , 1992, Statistics in medicine.